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Abstract 
Background: In a proportion of patients with HIV-associated tuberculosis who develop 
paradoxical immune reconstitution inflammatory syndrome (IRIS), the clinical course of IRIS 
is prolonged necessitating substantial health care utilization for diagnostic and therapeutic 
interventions. This phenomenon has not been systematically studied to date. We aimed to 
determine the proportion of patients with prolonged TB-IRIS, as well as the clinical 
characteristics and risk factors for prolonged TB-IRIS.  
 
Methods: We pooled data from 2 prospective observational studies and a randomized 
controlled trial that enrolled patients with paradoxical TB-IRIS using the same diagnostic 
approach and clinical case definitions in Cape Town, South Africa. Prolonged TB-IRIS was 
defined as TB-IRIS symptoms lasting > 90 days. Risk factors for TB-IRIS were analysed 
using Wilcoxon rank sum test, Fisher’s exact test, multivariate logistic regression and Cox 
proportional hazards model. In a separate set of analyses, risk factors for relapsing after a 4-
week course of prednisone for treatment of TB-IRIS were analysed. 
 
Results: Two-hundred and sixteen patients with TB-IRIS were included. The median 
duration of TB-IRIS symptoms was 71.0 days (IQR=41.0-113.2). In 73/181 patients with 
sufficient follow-up (40.3%) IRIS duration was > 90 days. Six patients (3.3%) had IRIS 
duration > 1 year, mainly with nodal involvement. In univariate logistic regression analysis 
the following were significantly associated with IRIS duration > 90 days: lymph node 
involvement at initial TB diagnosis (p=0.02), drug-resistant TB (p=0.02), lymph node TB-
IRIS (p=0.0005) and not being hospitalized at time of TB-IRIS diagnosis (p=0.004). The 
association with lymph node TB-IRIS (p=0.02) and hospitalization status (p=0.05) remained 
significant in the multivariate logistic regression model. In the Cox proportional hazards 
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model, IRIS lymph node involvement was independently associated with lower hazards of 
IRIS resolution (HR 0.55, 95%CI=0.38-0.78). In univariate analysis those patients with lesser 
reductions in liver function abnormalities during prednisone treatment had a higher risk of 




Around 40% of patients with TB-IRIS have symptoms for more than 90 days. Lymph node 
IRIS involvement is an independent risk factor for a prolonged course and in the small 
proportion of patients (3%) with symptoms more than one year this usually manifests with 
lymph node involvement. Whether earlier recognition and treatment of lymph node TB-IRIS 
could reduce the risk of prolonged TB-IRIS needs to be evaluated. 
 
Trial registration: The randomized controlled trial was registered with Current Controlled 
Trials ISRCTN21322548.  
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Literature Review: HIV-associated tuberculosis, tuberculosis-associated immune reconstitution 
inflammatory syndrome (TB-IRIS) and prolonged TB-IRIS 
 
Introduction 
The objectives of this review were to evaluate the published literature for reported cases of a 
prolonged course of tuberculosis-associated immune reconstitution inflammatory syndrome (TB-
IRIS), its incidence, predictors, clinical manifestations, treatment and outcomes. We defined 
prolonged paradoxical TB-IRIS as TB-IRIS symptoms lasting more than 90 days. This was chosen 
because previous studies have reported a median duration of TB-IRIS of 1-3 months [1-7].  
 
There are indeed very few instances in the literature where a prolonged course of TB-IRIS has been 
described. In fact, there is a general limitation in the literature with regard to the reporting of this 
enigmatic clinical phenomenon, in that most studies to date have had a small study population, were 
cases series or single case reports, and were retrospective. I have, in addition, endeavoured to 
contextualize this clinical entity, by commencing with an overview of the literature on TB-IRIS in 
general and have included in this review a concise summary of the literature pertaining to the 
following aspects: 
 
1. The burden of HIV associated TB in sub-Saharan Africa 
2. The Immune reconstitution inflammatory syndrome (IRIS): types and, associated pathologies  
3. Paradoxical Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS):   
• Incidence, clinical course and manifestations 
• Spectrum of clinical manifestations 
• Morbidity and mortality related to TB-IRIS 
• Immunopathogenesis 
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• Diagnosis and case definitions 
• Validation of INSHI (International Network for the Study of HIV-associated IRIS) case 
definitions 
• Risk factors for paradoxical TB-IRIS 
• Treatment of TB-IRIS 
 




1. The burden of HIV associated TB in Sub-Saharan Africa 
 
The Human Immunodeficiency Virus (HIV) and tuberculosis (TB) are leading global causes of 
mortality and morbidity [8]. Sub-Saharan Africa bears the brunt of the dual epidemic, accounting for 
approximately 78% of the estimated world burden in 2013 as reported by the World Health 
Organisation [9] People living with HIV are 29 times more likely to develop active TB disease than 
persons without HIV [9]. Highly active antiretroviral therapy (ART) dramatically decreases the 
mortality and the incidence of opportunistic infections in patients with advanced HIV infection, 
including those co-infected with TB [8].  
 
2. The Immune Reconstitution Inflammatory Syndrome (IRIS) 
 
The immune restoration associated with ART however may result in initial clinical deterioration due 
to immunopathological reactions in patients with underlying opportunistic infections [10]. The 
immune reconstitution inflammatory syndrome (IRIS), (also known as immune reconstitution 
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syndrome, immune reconstitution disease, or immune restoration disease), is a widely recognised 
phenomenon that can complicate ART and results from the rapid restoration of pathogen-specific 
immune responses to opportunistic infections [11]. It may cause either worsening symptoms of an 
already diagnosed infection which showed initial improvement on appropriate treatment prior to 
ART termed “paradoxical IRIS” or it may cause new symptoms of a subclinical infection to manifest 
which is referred to as “unmasking IRIS”. Both entities are often accompanied by a marked 
inflammatory response. IRIS has been associated with a wide spectrum of pathologies including 
infections with mycobacteria (both tuberculosis and non-tuberculous mycobacteria), viruses, fungi; 
cancers such as Kaposi’s Sarcoma and non-Hodgkins lymphoma; Progressive Multifocal 
Leukoencephalopathy (PML) as well as non-AIDS illnesses such as sarcoidosis and rheumatic 
diseases [12]. The most commonly occurring IRIS phenomena in our context are those related to TB 
and deep fungal infections particularly cryptococcal meningitis [11]. 
IRIS typically occurs in the early weeks of ART with several studies reporting a median duration to 
onset of symptoms of a few weeks after commencing ART [1, 13, 14] but this varies depending on 
the cause of IRIS. A relatively large prospective observational study reported TB-IRIS symptom 
onset at a median of 14 days (interquartile range, 7–25 days) after the initiation of combination ART 
in a series of 100 patients with suspected IRIS, already on TB treatment prior to ART initiation [15]. 
 
3. Paradoxical Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-
IRIS) 
 
Incidence, clinical course and manifestations 
Given the very high burden of TB in patients infected with HIV in many low and middle income 
countries [8], many patients entering ART programmes already have a diagnosis of tuberculosis or 
develop tuberculosis following ART initiation. Locally, Lawn et al. [16] reported that 238 (25%) of 
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944 patients attending a community-based ART programme in South Africa were receiving 
tuberculosis treatment at ART initiation. Sharma et al. [17] reported that 237 (38%) of 627 patients 
studied had TB at initiation of ART at a tertiary centre in India. 
TB-IRIS complicates early ART in a considerable proportion of HIV-infected patients started on 
therapy in resource-limited countries. Paradoxical TB-IRIS is reported to occur in 8 – 54% of 
patients starting ART while on anti-tubercular therapy [11, 18-19]. The typical clinical course of this 
entity is that an untreated HIV infected individual, with newly diagnosed TB is initiated on anti-
tuberculosis therapy resulting in clinical improvement and stabilization. However, with the 
subsequent introduction of ART, IRIS presents as the development of recurrent, worsening or new 
symptoms or signs of TB such as fever, respiratory symptoms, lymph node enlargement often with 
abscess formation, or new or deteriorating radiological manifestations, within the early weeks of 
ART [11].  
TB-IRIS may have a wide range of clinical manifestations often with involvement of multiple organ 
systems, reflecting widespread dissemination of Mycobacterium tuberculosis in those with profound 
immunosuppression [20]. In addition to those previously mentioned, patients may present with new 
or worsening serositis (pleural effusions, ascites or pericardial effusions), psoas abscesses or other 
cold abscesses and central nervous system involvement (e.g. meningitis, enlarging tuberculomas). 
Another common manifestation is that of a granulomatous hepatitis (Hepatic TB-IRIS) [21-22] which 
usually presents as a tender hepatomegaly associated with elevated serum concentrations of 
predominantly the bile canalicular hepatic enzymes but without evidence of biliary duct dilatation or 
obstruction on ultrasound. This phenomenon may occur independently but most often accompanies 
TB-IRIS at another anatomical site eg. respiratory involvement. It is important to recognize this 
clinical entity which can sometimes be misdiagnosed as drug induced liver injury leading to 
unnecessary interruptions in ART and TB treatment. Other causes of liver enzyme elevation need to 
be excluded prior to diagnosis of hepatic TB-IRIS such as exacerbation of Hepatitis B and C. 
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Morbidity and mortality related to TB-IRIS 
TB-IRIS causes substantial morbidity, often resulting in hospitalization and / or the need for 
diagnostic and therapeutic procedures [2, 23]. Burman et al. [2] reported that in their study 24% of 
patients required surgical drainage of nodal or soft tissue abscesses, 44% required needle aspirations 
and strikingly 16% of patients required recurrent aspirations of suppurative lymphadenopathy with 
up to 108 aspirations being performed on one of the patients in the study. Mortality related to TB-
IRIS is said to be infrequent ranging between 2.5-4% of patients [3, 12]. A systematic review of IRIS 
by Muller et al. published in 2010 [12] reported a mortality of 3.2% in patients with TB-IRIS. 
Patients with neurological TB-IRIS however represent an important exception in that their 
presentation may be particularly severe with a wide range of manifestations such as meningitis, 
intracranial tuberculomata, tuberculous brain abscesses, radiculomyelopathy and spinal epidural 
abscesses [24-26]. Pepper et al. [26] reported a combined mortality and loss to follow-up of 30% 
amongst patients with neurological TB-IRIS in their case series. 
 
Immunopathogenesis 
The currently proposed immunopathogenic mechanisms suggest that TB-IRIS arises as a result of 
rapid change in the innate response with consequent influence on the acquired response. TB-IRIS is 
associated with dysregulated inflammatory responses demonstrating an elevation in both effector and 
regulatory cytokines whose release is influenced by Mycobacterium tuberculosis antigen load in 
patients. The pattern of cytokine elevation seen in TB-IRIS suggests significant involvement of the 
innate immunity. Serum levels of CRP have been noted to be higher in both unmasking and 
paradoxical TB-IRIS cases than non-IRIS controls at baseline, and the CRP levels increase further at 
the time of TB-IRIS development. Antigen-specific CD4+ T cell restoration and expansion have been 
shown in certain studies to have a significant association with TB-IRIS but findings in the literature 
vary, a possibility being that CD4+ T-cell expansion is a consequence, rather than the cause of the 
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syndrome. Although increases in several cellular and immunological factors have been found to be 
associated with TB-IRIS, their predictive value is not well established. It is hoped that improved 
understanding of the interconnected network of innate and adaptive immunity in TB-IRIS 
pathogenesis will lead to the identification of biomarkers that can be used in prediction and diagnosis 
as well as recognizing new targets for therapeutic interventions. 
 
Diagnosis and case definitions 
Making the diagnosis of TB-IRIS can be challenging given the absence of a diagnostic test, or 
validated biomarker. Prior to 2008 diagnosis was based on expert opinion case definitions published 
in the literature. The most widely used definitions were those proposed by French et al. in 2004 [28], 
who described major and minor criteria for the diagnosis of IRIS in general (i.e. not disease specific) 
and in 2006, there were 2 other proposals for case definitions published. Shelburne et al. [29] also 
described general diagnostic criteria for IRIS, while Colebunders et al. [30] published a case 
definition specific for TB-IRIS describing criteria for suspected cases and confirmed TB-IRIS cases. 
These criteria included a combination of clinical features, radiological findings as well as 
immunological and virological laboratory parameters, with a fall in HIV-1 RNA concentration and/or 
a rise in the CD4+ T cell count being a core part of confirming the diagnosis. Due to the high cost of 
the immunological and virological tests these criteria are rendered largely impractical for use in 
resource-limited settings where the highest burden of opportunistic diseases and IRIS exist. 
Subsequently the development of consensus case definitions for TB-IRIS by the International 
Network for the Study of HIV-associated IRIS (INSHI) [11], has been instrumental in facilitating 
clinical diagnosis in addition to providing for standardisation of research definitions to enable greater 
understanding and insight into this condition. These criteria emerged from a consensus meeting in 
Kampala, Uganda where 97 TB-IRIS researchers from 16 countries on six continents were in 
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attendance and included delegates from a variety of disciplines and representatives from the World 
Health Organization (WHO).  
These criteria are particularly beneficial in resource-constrained environments where access to 
expensive laboratory parameters and radiological investigations are often limited and are not a pre-
requisite for diagnosis in the INSHI criteria. The authors of the INSHI document proposed that 
omission of these laboratory parameters would not substantially compromise case definitions for TB-
IRIS since IRIS frequently develops shortly after initiation of ART and before any measurable 
increase in peripheral blood CD4 cell count. Furthermore, most ART-naïve patients adhering to 
therapy have substantial reductions in viral load in the early months of treatment [11]. Therefore the 
inclusion of viral load changes in case definitions is largely redundant in the context of a patient 
adherent to therapy. 
 
Validation of INSHI case definitions 
Several studies have subsequently addressed validation of these case definitions with both 
retrospective [17, 31], and prospectively collected data [32].  Sharma et al. conducted a retrospective 
study in India using the consensus case-definition in 627 HIV infected patients initiating ART and 
concluded that it provides a useful tool in resource-limited settings for the diagnosis of paradoxical 
TB-IRIS [17]. Haddow et al. prospectively studied 498 HIV infected patients commencing ART. 
Patients were followed up over a 24 week period and all possible TB-IRIS events were assessed 
using both consensus expert opinion and INSHI case definition.  The authors reported good 
agreement between the 2 diagnostic modalities for both paradoxical and unmasking TB-IRIS, 
supporting the use of the INSHI case definition in clinical practice and research [32]. 
 
Risk factors for paradoxical TB-IRIS                                                                                                  
A number of risk factors have been identified.  These include a low baseline CD4 count prior to ART 
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[1, 14], particularly a CD4 count < 50 cells/uL [5-6], a marked rise in CD4 count with 
commencement of ART [1, 13], and a short duration between the start of TB treatment and the 
introduction of ART [2, 14, 29] as well as TB factors such as the presence of extra-pulmonary or 
disseminated TB at the time of TB diagnosis [1-2, 4, 13]. 
 
Treatment of TB-IRIS 
Older studies employed a variety of strategies, either on their own or in combination, in attempt to 
manage this condition, including the interruption of ART, the use of non steroidal anti-inflammatory 
drugs (NSAID), glucocorticoid therapy as well as a wait and see approach [13]. Studies specifically 
addressing the treatment of paradoxical TB-IRIS are rare and based almost exclusively on expert 
opinion, except for the randomized placebo controlled trial of prednisone for the treatment of 
paradoxical TB-IRIS conducted by Meintjes et al. which demonstrated that a 4-week course of 
prednisone reduced the need for hospitalization and outpatient therapeutic procedures and resulted in 
more rapid improvements in symptoms, radiography, markers of inflammation, performance, and 
quality of life [23].  
It is important to investigate for other causes of clinical deterioration prior to glucocorticoid therapy, 
among them being poor adherence to TB therapy, drug toxicity, other opportunistic infections 
(particularly in patients with smear negative TB or extra-pulmonary TB where the initial TB 
diagnosis was not microbiologically confirmed) and failure of TB treatment due to drug resistance 
[11]. Undiagnosed rifampin-resistant TB has been reported to be present in up to 10% of patients that 
present with paradoxical TB-IRIS [15]. 
 
4. Prolonged Tuberculosis-associated immune reconstitution inflammatory syndrome 
                                                                                                                                                            
With regards to the reporting of TB-IRIS in the literature in general, Leone et al. in their systematic 
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review of IRIS associated with Mycobacterium tuberculosis between 1990 and 2007, noted the 
limitation in the literature in that most of the original manuscripts had a small population, were cases 
series or single case reports, and were retrospective. The pooled number of patients in that systematic 
review was 238 patients from 51 articles, with the largest study reporting on 21 TB-IRIS cases [10].  
 
The natural history or full clinical course of TB-IRIS has not been thoroughly described. While most 
cases are self-limiting, a proportion of patients, will require hospital admission and / or recurrent 
diagnostic and therapeutic procedures to manage their TB-IRIS manifestations. This is particularly 
the case for the subgroup of patients who experience a protracted clinical course of TB-IRIS. The 
median duration of symptoms in several observational studies has been reported to be 1-3 months   
[1-7] but in a subset of patients the condition may last for a considerably longer period of time [1-2, 
6-7, 11].  
 
There are several instances in the literature where a prolonged course of mycobacterial IRIS is 
described and most cases have been reported in relation to a different infection with non-tuberculous 
mycobacteria (NTM). Phillips et al. [33] reported on 51 patients with NTM IRIS and the median 
duration of IRIS symptoms was 6 months (range: 0–27 months) with ongoing symptoms at last 
follow-up in 5 patients (median duration of follow up of 29 months). Riddell et al. [34] described the 
long-term outcomes of Mycobacterium avium complex (MAC) IRIS in 20 patients: 16 (80%) 
responded to treatment and were disease free after a mean of 17.4 months of therapy for MAC IRIS. 
Four patients had persistent or relapsing disease despite 27 months of treatment. 
 
Prolonged TB-IRIS has not been systematically studied but presents one of the most important 
challenges for treatment programmes and clinicians in the management of HIV and TB co-infection. 
While there are case reports of patients with a prolonged course of TB-IRIS this phenomenon has not 
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been well characterized to date. The Table below summarises studies that reported TB-IRIS duration 
or described prolonged TB-IRIS cases. In a case series by Olalla et al. [7],  who looked 
retrospectively at 33 patients who were HIV infected and had proven mycobacterial disease (7 MAC 
and 26 TB), 9 patients in the group had paradoxical reactions (27%; 8 had TB and 1 MAC). The 
length of the paradoxical response was very variable (between 19 days and more than 395 days), with 
a median of 57 days, but it was longer in those patients whose paradoxical responses manifested the 
appearance or enlargement of lymph nodes (median duration 195 days). Huyst et al. [35] reported a 
case with 2 episodes of IRIS associated with Mycobacterium tuberculosis, the first episode occurring 
soon after initiation of ART and the second episode occurring almost 4 years after commencement of 
ART when the patient’s CD4 lymphocyte count was around 300 cells/ul and she was virologically 
suppressed at the time. 
 
In the more recent literature, the largest body of data with regard to TB-IRIS, including the reporting 
of IRIS durations, has emerged from the clinical trials exploring the optimal timing of ART in 
patients with HIV-TB co-infection. Luetkemeyer et al. in the STRIDE trial [5] reported an overall 
median TB-IRIS duration of 87 days (IQR 44-139 days) with a median of 92 days (IQR 46-134 days) 
in the subset of patients that received early ART (within 2 weeks after TB treatment initiation), and a 
median duration of 104 days (IQR 46-136) in patients with a CD4 cell count ≤ 50 cells/uL. This 
demonstrated that a significant number of patients (around 50%) in the trial experienced TB-IRIS 
symptoms that lasted longer than 90 days, which we defined as a prolonged course of IRIS in our 
study. 
 
Laureillard et al. [3] reporting on TB-IRIS in the CAMELIA (Cambodian early versus late initiation 
of ART) study found a median TB-IRIS duration of 7.4 weeks (IQR 4-19.8 weeks), amongst the 
largest cohort of TB-IRIS patients published to date (n=155). Locally, Naidoo et al [6] in a secondary 
	   18	  
analysis of the SAPIT (Starting Antiretroviral Therapy at Three Points in Tuberculosis) trial 
conducted in Durban reported on 80 patients with TB-IRIS. They found a median duration of TB-
IRIS of 70.5 days in the early integrated ART arm (initiation of ART within 4 weeks of TB treatment 
initiation) compared to a median TB-IRIS duration of 34 days in the late integrated arm (initiation of 
ART within 4 weeks of completion of the intensive phase of tuberculosis treatment) of their study. 
They concluded that the early integrated group demonstrated significantly higher IRIS rates, longer 
time to IRIS resolution, and more severe cases of IRIS requiring hospitalization.  
The overall recommendation that has emerged as a result of these 3 trials is that ART initiation as 
early as 2 weeks after commencement of TB treatment is strongly advocated in HIV-TB co-infected 
patients who are severely immunocompromised especially in those with a CD4 count less than 50 
cells/uL, due to the survival benefit which outweighs the increased risk of TB-IRIS associated with 
early ART. Fear of TB-IRIS in this group of patients should therefore not be an impediment to early 
ART in resource limited, high burden settings [3] but patients need to be monitored closely in the 
first months of ART for the complications of TB-IRIS to enable appropriate management of this 
condition which can sometimes be severe, and in rare cases fatal. 
 
Other reports on prolonged cases of TB-IRIS in the literature are very few and tend to be single cases 
or small numbers of patients within TB-IRIS studies that reported IRIS duration. Burman et al. [2] 
reported on 25 patients that developed TB-IRIS within their study. Forty percent  (n=10) had a TB-
IRIS duration of more than 90 days (range 91-511 days) and 54% of these patients manifested with 
suppurative lymphadenopathy. Breton et al. [13] looked at different strategies in the management of 
34 patients with TB-IRIS and found an initial median IRIS duration of only 20 days (IQR 15-33), 
however 32% of patients relapsed with TB-IRIS symptoms in their series with 4 long term relapsing 
cases with durations of 14 months, 20 months, 3 years and 4 years. The authors did not comment on 
the TB-IRIS manifestations in these prolonged cases. In a study from Brazil by Serra et al. [36] the 
	   19	  
mean TB-IRIS duration was 91 ± 30 days (n=10) and interestingly in this study, the sole clinical 
manifestation was lymph node enlargement. Michaelidis et al. [1] reported a median TB-IRIS 
duration of 2.53 months (range 0.53–14.97 months) with 1 patient manifesting with a discharging 




There are several limitations in the literature with regard to the description of TB-IRIS with most 
studies being retrospective and reporting on a small population of patients. The median duration of 
TB-IRIS symptoms reported across studies has been between 1-3 months. The aims of our study 
were to determine the proportion of patients that presented with a prolonged course of TB-IRIS 
which we defined as lasting greater than 90 days duration; to describe their clinical characteristics 
and to identify risk factors. This phenomenon is infrequently reported in the literature and yet may be 
an important aspect in the natural history and clinical course of the disease and represents a key 
management challenge in HIV programmes dealing with large numbers of patients with HIV-
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Prolonged cases  
reported 






14 Median 2.53 
(0.53–14.97) 
months 
1 patient had a discharging 
psoas abscess for 15 months 
Steroids 79%, IL-2 





80%, fever 57% 
Burman 
[2] 
25 Median 60 d  
(IQR 45-98) 
10 pts (40%) TB-IRIS 
duration >90 d range 91-
511d  
Four pts with duration 100-
511 d required recurrent 
aspiration of cold abscesses 
– up to 108 aspirations 
Steroids 4, needle 
aspiration 11 , 
surgical drainage 6 








155 Median 7.4 weeks  
(IQR 4-19.8) 
Not reported NSAIDs 36%, 
steroids 38% 
6 (3.9%) Lymphadenopathy 
77%, fever 68%, new 





61 Median 87 d (IQR 
44-139) 
Median IRIS duration for 
earlier ART group 92 d 
(IQR 46-134) n=42 & CD4 





No deaths lymphadenopathy 
59%, constitutional 





80 70.5 d (IQR 42-
151) Early 
integrated group, 
34 d (IQR 24-
118) Late 
integrated group 
2 unresolved TB-IRIS cases 
by end of follow up at 18 
months 






9 Median 57 days 





duration 195 days 
Steroids 22% 
NSAIDS 22% 
No deaths Lymphadenopathy 
67%, fever 67%, 
pulmonary infiltrates 
22%, meningitis 11% 
Breton 
[13] 
34 Median 20 d (IQR 
15–33) 
But 32% relapsed 
with TB-IRIS 
symptoms 
4 long term relapses of TB-
IRIS with durations: 14 
months, 20 months, 3 years 
& 4 years 
NSAIDs 3%, ART 
interruption 38%, 
ART interruption + 
steroids 9%, 














patients was 109 
days (IQR, 69–
141) 
Nil Steroids 100% 
ART interruption in 
1 patient 2 
2 (12.5%) 









No deaths Lymph node 




1 = Interleukin-2 and granulocyte macrophage colony-stimulating factor were administered to 
the patient with the discharging psoas abscess for 15 months with resultant resolution. 
2 = ART was interrupted during TBM-IRIS in 1 patient because of brainstem involvement. 
This patient made a full recovery and had no recurrent symptoms after recommencement of 
ART under prednisone cover. 
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Abstract 
Background: In a proportion of patients with HIV-associated tuberculosis who develop paradoxical 
immune reconstitution inflammatory syndrome (IRIS), the clinical course of IRIS is prolonged 
necessitating substantial health care utilization for diagnostic and therapeutic interventions. This 
phenomenon has not been systematically studied to date. We aimed to determine the proportion of 
patients with prolonged TB-IRIS, as well as the clinical characteristics and risk factors for prolonged 
TB-IRIS.  
 
Methods: We pooled data from 2 prospective observational studies and a randomized controlled trial 
that enrolled patients with paradoxical TB-IRIS using the same diagnostic approach and clinical case 
definitions in Cape Town, South Africa. Prolonged TB-IRIS was defined as TB-IRIS symptoms 
lasting > 90 days. Risk factors for TB-IRIS were analysed using Wilcoxon rank sum test, Fisher’s 
exact test, multivariate logistic regression and Cox proportional hazards model. In a separate set of 
analyses, risk factors for relapsing after a 4-week course of prednisone for treatment of TB-IRIS were 
analysed. 
 
Results: Two-hundred and sixteen patients with TB-IRIS were included. The median duration of TB-
IRIS symptoms was 71.0 days (IQR=41.0-113.2). In 73/181 patients with sufficient follow-up 
(40.3%) IRIS duration was > 90 days. Six patients (3.3%) had IRIS duration > 1 year, mainly with 
nodal involvement. In univariate logistic regression analysis the following were significantly 
associated with IRIS duration > 90 days: lymph node involvement at initial TB diagnosis (p=0.02), 
drug-resistant TB (p=0.02), lymph node TB-IRIS (p=0.0005) and not being hospitalized at time of 
TB-IRIS diagnosis (p=0.004). The association with lymph node TB-IRIS (p=0.02) and 
hospitalization status (p=0.05) remained significant in the multivariate logistic regression model. In 
the Cox proportional hazards model, IRIS lymph node involvement was independently associated 
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with lower hazards of IRIS resolution (HR 0.55, 95%CI=0.38-0.78). In univariate analysis those 
patients with lesser reductions in liver function abnormalities during prednisone treatment had a 
higher risk of relapse after stopping prednisone, but no significant associations remained in 
multivariate analysis.  
 
Conclusions:  
Around 40% of patients with TB-IRIS have symptoms for more than 90 days. Lymph node IRIS 
involvement is an independent risk factor for a prolonged course and in the small proportion of 
patients (3%) with symptoms for more than one year this usually manifests as lymph node 
involvement. Whether earlier recognition and treatment of lymph node TB-IRIS could reduce the risk 
of prolonged TB-IRIS needs to be evaluated. 
 
Trial registration: The randomized controlled trial was registered with Current Controlled Trials 
ISRCTN21322548.  
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Introduction 
 
Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an 
immunopathological reaction occurring in 4-54% patients who start antiretroviral therapy (ART) 
while on treatment for tuberculosis (TB) [1-3]. Mortality due to TB-IRIS is infrequent [4, 5]. 
However, TB-IRIS results in substantial morbidity, necessitating hospitalisation and other health care 
utilisation for diagnostic and therapeutic procedures [6, 7], particularly when TB-IRIS has a 
protracted clinical course. The median duration of TB-IRIS symptoms reported from several 
observational studies and clinical trials has been 1-3 months [4, 6-11]. However, the condition may 
last considerably longer, even more than one year in certain cases [2, 6, 9-12]. 
 
The risk factors and clinical features of those patients who develop a prolonged course of TB-IRIS 
symptoms have not been systematically studied. We conducted this study to determine what 
proportion of TB-IRIS patients experienced a prolonged clinical course (defined as symptoms lasting 
> 90 days), their clinical characteristics, outcomes, and risk factors for this phenomenon. In a second 
set of analyses we determined predictors of relapse of TB-IRIS symptoms after stopping a 4-week 
course of prednisone treatment in the context of a randomized placebo-controlled trial (RCT) of 
prednisone for the treatment of TB-IRIS [13]. The rationale for including this second set of analyses 
was that patients who relapse after a course of prednisone may have a more refractory form of TB-
IRIS that may share common risk factors with prolonged TB-IRIS. 
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Methods 
Study design 
We pooled data from 3 prospective studies of TB-IRIS that our group conducted in Cape Town, 
South Africa between 2005 and 2010 [13-15]. Data from eligible TB-IRIS cases assessed and 
followed up in these studies were included in this combined post hoc analysis. One of these studies 
was a randomized controlled trial (RCT) and the other 2 were prospective observational cohort 
studies. The RCT was conducted at GF Jooste Hospital with enrollment between June 2005 and 
December 2007. This was a secondary-level university-affiliated hospital serving communities with 
high HIV/TB co-infection rates. Patients were generally started on TB treatment and ART in primary 
care clinics and referred to the hospital with suspected TB-IRIS. Those enrolled in this trial (n=110) 
had paradoxical TB-IRIS that fulfilled a study case definition. The treatment intervention tested was 
a 4-week course of prednisone (1.5 mg/kg/day for 2 weeks followed by 0.75mg/kg/day for a further 2 
weeks). The trial was placebo-controlled with 1:1 randomisation. Trial design allowed patients who 
deteriorated on or relapsed after stopping study drug to be commenced on open-label prednisone at 
clinician discretion. The trial duration was 12 weeks, but if patients still had TB-IRIS symptoms at 12 
weeks follow-up was prolonged until TB-IRIS had resolved [13]. 
 
The first observational cohort study was also conducted at GF Jooste Hospital contemporaneously 
with the RCT [14]. Sixty-one patients with TB-IRIS who were seen prior to the RCT or were 
ineligible for the RCT (for example because of neurological TB-IRIS) were enrolled and followed up 
as outpatients until resolution of TB-IRIS symptoms between February 2005 and July 2006. The 
second observational cohort study was conducted at Brooklyn Chest TB Hospital, also in Cape 
Town, with recruitment between May 2009 and November 2010 [15]]. This was a study of ART-
naïve patients who required hospitalization for the treatment for HIV-associated TB and who started 
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ART while in hospital and were followed for at least 12 weeks. Forty-seven TB-IRIS cases were 
diagnosed in this study and patients were followed for longer than 12 weeks if TB-IRIS was ongoing. 
 
TB was diagnosed microbiologically (smear or culture) or using WHO guidelines for the diagnosis of 
smear-negative pulmonary and extrapulmonary TB [16]. Patients were treated according to national 
guidelines for TB and HIV. During the study periods TB cases received 6 months of therapy 
(rifampin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampin and isoniazid 
for 4 months). The retreatment regimen included the addition of streptomycin for the first 2 months 
of an 8-month regimen. Routine TB drug susceptibility testing (DST) was 
not performed for new TB cases. Patients receiving retreatment and patients not responding to TB 
treatment may have had DST performed. DST was only performed for rifampin, isoniazid, and 
ethambutol using culture-based techniques as previously described [14]. When drug resistant TB was 
diagnosed a standard multi-drug resistant TB regimen was prescribed. First-line ART in South Africa 
was stavudine, lamivudine, and either nevirapine or efavirenz. Efavirenz was preferred for patients 
receiving rifampin-based TB treatment. Patients with a CD4 cell count <200 cells/μl and/or World 
Health Organization stage 4 disease were eligible to commence ART. In April 2010, the guidelines 
changed and tenofovir replaced stavudine, and TB patients were eligible for ART with a CD4 count < 
350 cells/μl. Laboratory test were performed by the National Health Laboratory Services (NHLS). 
 
Inclusion and exclusion criteria 
All patients included in this study fulfilled the International Network for the Study of HIV-associated 
IRIS (INSHI) consensus case definition for paradoxical TB-IRIS [2] with one exception. Patients 
with rifampicin resistant TB were included in the first set of analyses of prolonged TB-IRIS. We 
have previously described an overlap of TB-IRIS and rifampicin-resistant TB [14] and for this reason 
when a patient with drug resistant TB was also considered to have TB-IRIS they were not excluded 
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from the analyses of prolonged TB-IRIS as we wished to determine if underlying drug resistant TB 
was a potential risk factor for a more prolonged course of TB-IRIS despite appropriate treatment. 
However, rifampicin resistant TB was an exclusion criterion for the prednisone RCT, therefore the 
second set of analyses of patients relapsing after stopping prednisone did not include patients with 
known rifampicin resistance. 
 
Study definitions 
Pulmonary TB-IRIS was defined as new, recurrent or worsening respiratory symptoms and/or a 
worsening chest radiograph pulmonary infiltrate. Lymph node TB-IRIS was defined as enlarging 
peripheral lymph nodes on clinical examination, or thoracic nodes on chest radiograph or abdominal 
nodes on ultrasound or CT scan. Abdominal TB-IRIS was defined by abdominal symptoms at the 
time of TB-IRIS (eg. abdominal pain), clinical hepatomegaly or features of abdominal TB on 
ultrasound (eg. lymphadenopathy). Multi-organ TB-IRIS was defined by the presence of TB-IRIS 
symptoms, clinical signs or radiological/ultrasound abnormalities that involved more than 1 organ 
system (eg. pulmonary and nodal). These definitions relate to any features present at TB-IRIS 
presentation or that occurred at any time during the course of the TB-IRIS episode. 
 
Prolonged paradoxical TB-IRIS was defined as TB-IRIS symptoms lasting more than 90 days. This 
was chosen because previous studies have reported a median duration of TB-IRIS of 1-3 months [4, 
6-11]. IRIS symptom onset date was as reported by the patient. IRIS end date was recorded as date of 
resolution of all symptoms attributed to TB-IRIS. If a patient was asymptomatic, but had only a 
persistent pulmonary infiltrate, tachycardia or hepatomegaly this did not constitute ongoing IRIS. In 
patients manifesting with lymph node enlargement due to TB-IRIS, IRIS resolution date was 
recorded when patients complained of no symptoms related to lymph nodes, and nodes had reduced 
in size by more than half of initial size or when node(s) were less than 2cm in maximal diameter. The 
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term procedure was used to denote all invasive diagnostic (eg. lumbar puncture) and therapeutic (eg. 
aspiration of pus collection) procedures. 
Data collection 
Clinical data regarding TB presentation and diagnosis, HIV history, TB-IRIS symptoms, 
corticosteroid treatment and duration, as well as laboratory results were extracted from the trial 
databases using a standard data extraction form. When necessary the source notes were reviewed to 
extract other relevant data. Data was entered onto a Microsoft Excel® spreadsheet. 
Statistical analyses 
Data analysis was performed using GraphPad Prism and R 3.0. Median and interquartile range (IQR) 
are presented for continuous variables and frequency and percentage for categorical variables. 
Changes in explanatory variables between follow up time points and baseline were calculated as 
follow up value minus baseline value. Duration was calculated in days. P-values were estimated from 
Fisher’s exact test (for categorical variables) and the Wilcoxon rank sum test (for continuous 
variables). P-values ≤ 0.05 were taken to be statistically significant. 
The first set of analyses (prolonged duration of TB-IRIS) was performed combining the 3 study 
databases (Figure 1). The duration of TB-IRIS symptoms was described for these patients. The 
clinical features of those patients with prolonged TB-IRIS (> 90 days and > 1 year) were described. 
Thereafter, factors associated with prolonged TB-IRIS were analysed in univariate analysis, followed 
by multivariate logistic regression analysis. The multivariate logistic regression model included all 
variables with p-value < 0.1 by univariate analysis and certain pre-specified adjustment variables (eg. 
gender). In the event of multiple variables measuring the same process alternate models were tested. 
A Cox proportions hazards model was developed in order to assess variables independently 
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associated with time to resolution of TB-IRIS. A competing risk analysis accounting for mortality 
was also performed. For the analyses of factors associated with prolonged TB-IRIS (>90 days) 
patients who were lost to follow up or died prior to 90 days and before IRIS resolution were not 
included in the univariate and multivariate logistic regression models. They were included in the Cox 
proportional hazards model and censored at death or loss to follow-up if these occurred before IRIS 
resolution. They were similarly included in the competing risks analysis. 
 
In the second set of analyses (relapse after stopping prednisone) only patients randomised to the 
prednisone arm of the RCT were included. In this RCT we noted that while patients had more rapid 
symptom improvement with prednisone compared with placebo, a subset of patients relapsed after 
completing a 4-week course of prednisone. Many of these patients required further corticosteroid 
therapy for several months to control the symptoms of IRIS: the median duration of open label 
prednisone being 84 days [13]. The outcome of interest in these analyses was relapse of TB-IRIS 
symptoms after stopping 4 weeks of prednisone, such that the clinician took the decision to restart 
open label prednisone. Factors associated with TB-IRIS relapse were analysed in univariate analysis 
and a multivariate logistic regression model was developed using the same criteria described above. 
 
Ethical approval 
This study was approved by the Human Research Ethics Committee of the University of Cape Town 
(HREC REF: 300/2012). All three individual studies had also received approval from this ethics 
committee. 
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Results 
 
Two-hundred and sixteen patients were diagnosed with paradoxical TB-IRIS across the 3 studies. 
One-hundred and eighty one patients were included in the initial analyses that compared patients with 
IRIS duration ≤ 90 days versus > 90 days. Reasons for exclusion are shown in Figure 1. In the Cox 
proportional hazards and competing risks models 212 patients were included (in 4 patients the ART 
start date was not known). The characteristics of the 212 patients are summarized in Table 1. 
 
Among the 181 participants included in the initial analyses, 116 (64.1%) were female and median age 
was 31 years (IQR=27-36). The median CD4 count prior to ART was 53 cells/μl (IQR=29-94) and at 
first TB-IRIS assessment was 117 cells/μl (IQR=71–218). The TB diagnosis was made by culture of 
Mycobacterium tuberculosis in 97 (53.6%), positive smear for acid-fast bacilli in 41 (22.6%) and 
clinical/radiological diagnosis in 43 (23.8%). One-hundred and fifteen patients (63.5%) had extra-
pulmonary involvement at TB diagnosis. Median duration from starting TB treatment to ART was 
56.0 days (IQR=31.0–81.3). Median duration from ART to TB-IRIS symptom onset was 13.5 days 
(IQR=7.0-19.3 days). The most frequent organ systems involved by TB-IRIS were: abdominal 
(n=140, 77.3%), pulmonary (n=72, 39.8%) and lymph nodes (n=71, 39.2%). In 150 patients (82.9%) 
there was multi-system involvement. At the time of TB-IRIS diagnosis among the 181 patients, 83 
(45.9%) were hospitalized (for 5 patients this data was missing). 
 
The median duration of TB-IRIS symptoms was 71.0 days (IQR=41.0-113.2) for those who had a 
known TB-IRIS start and resolution date (n=172, this excluded all those who died or were lost to 
follow-up prior to TB-IRIS resolution even if > 90 days). In the 181 patients, IRIS duration was 
longer than 90 days in 73 (40.3%) and 6 (3.3%) had IRIS duration of over one year. The distribution 
of duration shown in Supplementary Figure 1. 
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One-hundred and twenty seven of the 216 patients (58.7%) received prednisone treatment. 111 of the 
181 patients (61.3%) received prednisone for a median 42 days (IQR=28-91). This included 
prednisone received as study drug or open-label prednisone in the RCT and as TB-IRIS treatment in 
the observational cohorts. In the RCT and in clinical practice standard practice was to start 
prednisone at a dose of 1.5mg/kg/day. Outside of the RCT, clinician practice was to taper prednisone 
according to symptom response. 
 
Of the 216 patients, 16 (7.4%) were known to have died a median of 33.5 days after TB-IRIS onset 
(IQR=28-61.5). 14 patients died within 90 days and 2 patients died after 90 days. TB-IRIS was 
considered the main cause of death in 5 of the 16 deaths. The most frequent other cause of death 
among the TB-IRIS cases was sepsis (n=5). 
 
Characteristics of patients with prolonged TB-IRIS 
In the 73 patients with TB-IRIS lasting > 90 days the following features were present either at 
presentation or at some time during the course of their TB-IRIS: lymph node involvement in 40 
(54.8%), pulmonary involvement in 23 (31.5%), abdominal involvement in 59 (80.8%) and pleural, 
pericardial effusions or ascites in 18 (24.7%). In 64 (87.7%) TB-IRIS was multi-system. There were 
2 deaths among the patients with prolonged TB-IRIS (>90 days). The characteristics, treatment and 
clinical course of the 6 patients who had TB-IRIS symptom duration > 1 year are summarized in 
Table 2. 
 
Factors associated with prolonged TB-IRIS 
Comparisons between those with prolonged IRIS and those with IRIS duration ≤ 90 days are shown 
in Table 3. In univariate statistical comparisons the following variables were significantly associated 
	   39	  
with IRIS duration > 90 days: drug-resistant TB, lymph node involvement at initial TB diagnosis, 
lymph node TB-IRIS and not being hospitalized at the time of TB-IRIS diagnosis. Treatment with 
corticosteroids was not associated with prolonged TB-IRIS nor did duration between TB treatment 
and ART initiation influence the development of prolonged TB-IRIS. 
 
In univariate logistic regression analysis (Table 4; unadjusted results) the following variables were 
significantly associated with IRIS duration > 90 days: lymph node involvement at initial TB 
diagnosis (OR 2.36, 95%CI=1.18-4.76; p=0.02), drug-resistant TB (OR 4.13, 95%CI=1.32-15.56, 
p=0.02) and lymph node TB-IRIS (OR 3.01, 95%CI=1.63-5.65; p=0.0005). Hospitalization at the 
time of TB-IRIS diagnosis was associated with TB-IRIS resolving before 90 days (OR 0.40, 
95%CI=0.22-0.75; p=0.004) as was cohort (OR for observational compared to RCT 0.29, 
95%CI=0.12-0.62, p=0.002; and OR for BCH compared to RCT 0.06, 95%CI=0.01-0.18; p<0.0001). 
Hospitalisation and not cohort were included in the multivariate models due to perfect separation if 
both were included. In the multivariate logistic regression model (Table 3; adjusted results) lymph 
node enlargement at time of TB-IRIS demonstrated a statistically significant association with IRIS 
duration > 90 days (aOR 2.27, 95%CI=1.13-4.59; p=0.02). Hospitalization was associated with an 
IRIS duration ≤ 90 days (aOR 0.5, 95%CI=0.25-0.99; p=0.05). Drug-resistant TB demonstrated a 
trend towards but did not reach statistical significance in association with prolonged TB-IRIS (aOR 
3.26, 95%CI=0.97-12.99; p = 0.07).  
 
Due to the potential bias around the BCH cohort and hospitalization (as all patients in the BCH 
cohort were admitted to a TB hospital from the time of starting ART whereas in the other 2 studies 
patients were only admitted to a general hospital for shorter periods based on severity of illness at the 
time), a sensitivity analysis was performed excluding all individuals in the BCH cohort. Both 
univariate and multivariate regression models were assessed (See	  appendix	  3:	  	  Supplementary	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Table	  1) and although, as expected, the number of variables with statistically significant associations 
decreased, the direction and size of the effects remained largely the same. However, hospitalization 
was no longer associated with prolonged TB-IRIS (aOR 1.16, 95%CI=0.53-2.57, p=0.71). 
 
The Cox proportional hazards model (Table 5) included 212 patients for whom the TB-IRIS start date 
was known and a multivariate model was run based on predictors of interest as indicated by previous 
analyses and pre-specified variables. Predictors included were: initial TB lymph node involvement, 
TB-IRIS lymph node involvement, TB-IRIS pulmonary involvement, drug-resistant TB, as well as 
age, gender and hospitalisation. IRIS lymph node involvement was statistically significantly 
associated with a lower hazard of IRIS resolution (HR 0.55, 95%CI=0.38-0.78; p = 0.0009) in both 
the full model and the model run without the BCH cohort (HR 0.60, 95%CI=0.40-0.89; p = 0.01, See	  
appendix	  3:	  Supplementary	  Table	  2). Additionally, competing risks models were analysed to 
account for the competing risk of death and IRIS resolution and the model demonstrated similar 
findings (See	  appendix	  3:	  Supplementary	  Table	  3).	  In Supplementary Figure 2, the Kaplan-Meier 
plot demonstrates more rapid TB-IRIS resolution for those without lymph node TB-IRIS compared to 
those with TB-IRIS with lymph node involvement (p < 0.0001; log-rank test).  
 
Factors associated with TB-IRIS relapse after stopping prednisone in RCT 
Those participants who completed 4 weeks of prednisone in the RCT as study drug who then 
developed a significant relapse of TB-IRIS symptoms after stopping, could be re-initiated on open 
label prednisone at study clinician discretion and in these analyses this was the endpoint of interest. 
Reasons for exclusion from these analyses are shown in Figure 2. Of the 43 RCT participants who 
completed 4 weeks of study prednisone 9 (20.9%) relapsed with TB-IRIS symptoms and were started 
on open-label prednisone. The median duration to commencing open-label prednisone after stopping 
study drug prednisone was 27 days (IQR=24-46). 
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Because there were a relatively small number of patients in this analysis, it was largely exploratory. 
The following variables were significantly associated with relapse in univariate analysis (Table 6 and 
Supplementary Figure 3): lower reduction in alkaline phosphatase from 0 to 4 weeks (p=0.03) and 
lower reduction in ALT from from 0 to 2 weeks (p=0.03) and 0 to 4 weeks (p=0.04). The following 
variables showed a non-significant trend towards being associated: lower reduction in alkaline 
phosphatase from 0 to 2 weeks (p=0.06), higher alkaline phosphatase concentration at week 2 
(p=0.08), longer duration from TB-IRIS to trial enrolment (and starting prednisone) (p=0.10), lower 
Karnofsky score at week 2 (p=0.09) and higher pulse rate at week 4 (p=0.09). The pulse rate at week 
4 in those who relapsed was a median116 beats/minute (IQR=99-118) versus 97 (IQR=80-107) in 
those who did not relapse. In a multivariate logistic regression model (data not shown) none of the 





In this combined analysis that included patients enrolled in 3 previously reported studies the duration 
of paradoxical TB-IRIS symptoms was a median of 71 days, with 40.3% of patients experiencing 
TB-IRIS symptoms lasting > 90 days. Six patients (3.3%) experienced a very protracted course of 
TB-IRIS with symptoms > 1 year duration. TB-IRIS lymph node involvement was independently 
associated with a longer duration of symptoms. 
The TB-IRIS case fatality rate in the combined cohort was 7.4%. This is higher than that reported in 
a meta-analysis (3.2%) [5], and this may reflect that our studies were conducted at a hospital level 
with patients having more severe clinical disease. Five of the 16 deaths were attributed to TB-IRIS 
(2.3%). In the CAMELIA trial mortality amongst the 155 TB-IRIS cases was higher than in our study 
(23 deaths among the 155 patients (14.8%) with 6 deaths attributed to TB-IRIS (3.9%)), likely a 
consequence of the advanced immunosuppression at ART initiation in the CAMELIA participants 
(median CD4 = 27 cells/μl) [4]. 
Hospitalization was associated with an IRIS duration ≤ 90 days (aOR 0.5, 95%CI=0.25-0.99; 
p=0.05). One possibility is that these findings were due to a cohort effect. In the BCH cohort of 
hospitalized TB-IRIS patients, because of close prospective follow up during early ART, TB-IRIS 
was diagnosed early and treated promptly with steroids when necessary thereby potentially reducing 
duration. This close follow-up may also have resulted in diagnosis of milder cases who may 
inherently have a shorter duration. 
Abdominal manifestations were the most frequent IRIS clinical feature in our study, which has not 
been reported in previous studies [17]. This was in part related to the permissive definition we used 
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for abdominal IRIS which included any patient who had TB-IRIS fulfilling INSHI criteria and who 
had any abdominal symptom (eg. abdominal pain or vomiting), hepatomegaly on clinical 
examination or abdominal ultrasound features of TB at the time of TB-IRIS. In a previous report, that 
included patients in this study, we reported over 50% of TB-IRIS patients had hepatomegaly and 
many had cholestatic liver function derangement at TB-IRIS presentation [14]. 
 
In the 6 patients who had TB-IRIS lasting > 1 year the prolonged features were nodal enlargement 
and suppuration and abscess formation, including cerebellar abscesses in 1 case. These patients 
received prolonged corticosteroids and 4 had one or more relapses when steroids were tapered or 
interrupted. However, in all of them steroids were eventually stopped long before IRIS resolution 
because of the clinical impression that they were no longer providing benefit and concerns regarding 
cumulative toxicity. The longest duration of steroid therapy was 308 days, and the longest duration of 
TB-IRIS was almost 4 years.  
 
Prolonged IRIS represents a key management challenge in ART programmes. Prolonged IRIS has 
best been described in patients with Mycobacterium avium complex (MAC) and other non-
tuberculous mycobacterial (NTM) infections. Phillips  [18] reported 51 patients with NTM IRIS in 
whom the median duration of IRIS symptoms was 6 months with a range of 0–27 months. Riddell 
[19] reported the long-term outcomes of MAC-IRIS for 20 patients: 16 responded to treatment and 
were disease free after a mean of 17.4 months of therapy for MAC IRIS, whereas 4 patients had 
persistent or relapsing disease despite 27 months of treatment. For paradoxical TB-IRIS several 
studies have reported on the duration of symptoms and cases with a prolonged course have 
previously been described. The median duration of TB-IRIS symptoms reported across studies has 
been between 40 and 90 days [4, 6-9, 11]. In the SAPiT trial those patients who started ART within 4 
weeks of TB treatment and developed TB-IRIS had a significantly longer duration of TB-IRIS 
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(median 71 days) compared to TB-IRIS cases who started ART 8-12 weeks after TB treatment 
(median 34 days) [10]. Unlike in the SAPiT and CAMELIA trials, most patients in our study had a 
long duration between starting TB treatment and commencing ART, median duration was 56.0 days 
(IQR=31.0–81.3)) In the CAMELIA trial, 155 cases of TB-IRIS were diagnosed, 77% with nodal 
involvement and 38% were treated with corticosteroids and 36% with non-steroidal anti-
inflammatory drugs. The median duration of IRIS was 7.4 weeks (IQR=4-19.8) [4]. Ollala et al [11] 
reported a very variable duration of mycobacterial IRIS (between 19 days and more than 395 days, 
median of 57 days), and duration was longer in those patients whose paradoxical responses 
manifested the appearance or growth of lymphadenopathies (median 195 days) similar to our study. 
Huyst et al [20] reported a case with 2 episodes of IRIS associated with TB; the first episode 
occurring soon after initiation of ART and the second episode occurring almost 4 years later. Similar 
to our findings, Burman et al reported 10/25 (40%) patients with TB-IRIS with a duration > 90 days. 
In 2 patients the duration of TB-IRIS was > 1 year and one required 108 aspirations of the IRIS 
lymph nodes [6]. Breton et al reported 4 among 34 patients who had long term relapses lasting 14 
months, 20 months, 3 and 4 years [12]. Naidoo et al reported 2 cases of TB-IRIS unresolved after 18 
months of trial follow-up in the SAPiT trial [10] and Michailidis et al a case with a discharging psoas 
abscess for 15 months [9]. 
 
The risk factors most consistently implicated in the development of TB-IRIS itself have been a low 
pre-ART CD4 count, short duration between starting TB treatment and ART and extra-pulmonary 
TB [21]. Neither of the first two were found to be associated with prolonged TB-IRIS whereas TB-
IRIS lymph node involvement (an extrapulmonary manifestation) was, suggesting there is a common 
risk factor for developing TB-IRIS itself and for a prolonged course of TB-IRIS.  In the CAMELIA 
trial mediastinal adenopathy was a risk factor for TB-IRIS [4] and in a Brazilian observational study 
superficial adenopathy was a TB-IRIS risk factor [22]. Nodal TB is also associated with a high 
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incidence of paradoxical reactions in HIV-negative TB patients [23]. Multiple lines of evidence 
therefore suggest TB in a nodal location increases the risk for inflammatory reactions and in our 
study a longer duration of these.  
 
In a separate analysis of factors associated with relapse of TB-IRIS symptoms after completing a 4-
week course of prednisone a lesser decrease in alkaline phosphatase and ALT on prednisone were 
significantly associated with relapse in univariate anlaysis. It is possible that these biomarkers reflect 
TB-IRIS liver involvement, which is common [14, 24], and their persistent elevation reflects ongoing 
granulomatous inflammation in the liver and this may predict that TB-IRIS systemic inflammatory 
process will flare up on stopping prednisone. Monocytes produce alkaline phosphatase during 
differentiation [25] and this is another potential source given their activation in TB-IRIS [26]. These 
findings are preliminary and need to be confirmed in larger cohorts. If validated, it may be possible to 
use alkaline phosphatase as a biomarker in assisting decisions regarding when to withdraw 
corticosteroid treatment in TB-IRIS. Interestingly pulse rate at week 4, likely reflecting systemic 
inflammatory state, was higher in patients who relapsed but this did not reach statistical significance. 
We had hypothesised that CRP, which decreased rapidly within the first 2 weeks of starting 
prednisone treatment for TB-IRIS [13] would predict relapse, but this was not the case.  
 
A limitation of this study is that it included patients enrolled in 3 separate studies introducing 
heterogeneity. One of the studies was an RCT, and 2 were observational studies. The RCT and 1 of 
the observational studies were done at a referral hospital and the other observational study at an 
inpatient TB hospital. This weakness was mitigated by the use of a similar diagnostic approach and 
case definition for TB-IRIS across the 3 studies. Also, the studies were all conducted by the same 
research group. Management protocols for TB-IRIS (apart from during the intervention period of the 
RCT) were similar across studies. Given that 2 of the studies were conducted at a referral hospital, 
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this may have excluded milder cases of TB-IRIS who were not referred from primary care, biasing 
the findings towards patients with more severe TB-IRIS. The location of the studies may also have 
contributed to loss to follow-up: loss to follow-up was defined as loss to follow-up at the referral or 
TB hospital and did not necessarily mean the patient was also lost to follow-up at their primary care 
HIV or TB clinic. In the analyses we included multiple variables and no correction for multiple 
comparisons was conducted. The analysis of relapse after completing 4 weeks of prednisone was 
limited by small sample size and analyses were therefore exploratory. Consistent with INSHI case 
definitions, some overlap existed in the definitions of lymph node TB-IRIS and abdominal TB-IRIS 
(with abdominal lymphadenopathy).  
 
A strength of this study overall is the large number of patients with paradoxical TB-IRIS included. 
This is to our knowledge the largest number of TB-IRIS patients to be included in a single analysis, 
and this allowed us to present important and novel findings with respect to the clinical course of TB-
IRIS and factors contributing. All patients fulfilled the INSHI case definition, apart from the 
inclusion of certain patients with drug resistant TB who were also considered to have TB–IRIS. 
 
In conclusion, around 40% of patients with TB-IRIS have a clinical course of symptoms lasting 
longer than 90 days. Lymph node IRIS involvement is an independent risk factor for a prolonged 
course. In the small proportion of patients (3%) with symptoms > one year this manifests with 
lymphadenitis or abscesses. Whether earlier recognition and treatment of lymph node TB-IRIS could 
reduce the risk for prolonged TB-IRIS needs to be evaluated in future studies. 
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Table 1: Baseline and TB-IRIS characteristics of the 212 patients included in Cox 
proportional hazards model 
 







74   (34.9%) 
Age (years) (n=212) 31 (27, 36) 






CD4 count prior to ART 
(cells/μl) (n=199) 
52 (28, 92.5) 
CD4 count at TB-IRIS (cells/μl) (n=95) 116 (71, 209.5) 
Previous TB (n=211) 55 (25.9%) 
Drug-resistant TB (n=212)1 21 (10%) 
Initial TB diagnosis with extra-
pulmonary (n=212) 
134 (63.2%)  
Initial TB diagnosis with lymph node 
involvement (n=212) 
50 (23.6%) 
Duration from TB treatment to ART 
(days)(n=211) 
56 (31, 83) 
Duration from ART to IRIS onset (days) 
(n=211) 
14 (7, 21) 
Hospitalised at time of IRIS diagnosis 
(n=206) 
107 (50.5%) 
IRIS lymph node involvement (n=212) 80 (37.7%) 
IRIS pulmonary involvement (n=212) 83 (39.2%) 
IRIS meningitis (n=209) 10 (4.7%) 
IRIS abdominal involvement (n=212) 154 (72.6%) 
IRIS multisystem involvement (n=212) 166 (78.3%) 
Pulse rate at IRIS (n=134) 120 (107.3, 132) 
C-reactive protein (mg/l) (n=195) 103 (63, 158.5) 
Haemoglobin (g/dl) (n=136) 9.1 (8, 10.4) 
White cell count 
(x 109/l) (n=132) 
5.7 (4.1, 8.1) 
ALT (IU/l) (n=180) 34 (22, 51) 
Alkaline phosphatase (IU/l) (n=164) 159 (107, 274.8) 
Corticosteroid treatment for TB-IRIS 125 (59.0%) 
 
 
Footnote for Table 1: 
 
Pulse rate and laboratory values refer to the value obtained when the patient was first assessed 
with TB-IRIS symptoms, unless otherwise stated. Numbers in brackets after the variable 
name refer to the number of patients for whom that variable was available. 
 
49	  
1 Among 21 patients with drug resistant TB 4 had rifampicin mono-resistance, 3 had isoniazid 
mono-resistance and 14 had resistance to rifampicin and isoniazid. 
Abbreviations: ALT = alanine transferase, ART = antiretroviral therapy, IRIS = immune 
reconstitution inflammatory syndrome, TB = tuberculosis, WHO = World Health 
Organisation. 
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Table 2: Characteristics, treatment and clinical course for 6 patients in whom TB-IRIS 





Footnote for Table 2: 
 
1 Patients 1, 2, 4 and 5 experienced recurrence of their TB-IRIS symptoms on tapering of 
steroids and required re-escalation of their steroid doses on 1 or more occasions. 
2 The initial TB-IRIS episode involved lymph nodes and resolved on prednisone then patient 
re-presented several months later with new neurological manifestations and multiple rim-
enhancing lesions in the cerebellum.  Brain abscess resection tissue cultured drug-susceptible 
Mycobacterium tuberculosis (MTB). 
3 Patient found to have rifampicin mono-resistant MTB (urine culture sent at diagnosis) at TB-
IRIS diagnosis. She was commenced on prednisone after commencement of appropriate 
treatment for rifampicin mono-resistant TB.   
4 Patient still had residual left iliac fossa mass on abdominal imaging at TB-IRIS resolution 
that was decreasing in size and was asymptomatic. 
 
Abbreviations: IRIS = immune reconstitution inflammatory syndrome, TB = tuberculosis. 





















persisted > 1 
year 
1 35 78 Extra-pulmonary TB 
(nodal) 
Nodal 746 (IRIS 
ongoing at 
last visit) 
70 1 Cerebellar 
tuberculomas / 
abscesses2 
2 34 160 Extra-pulmonary TB 
(nodal and miliary) 
Nodal 824 (IRIS 
ongoing at 
last visit) 
98 1 Supraclavicular 
nodes and large 
cold abscess 
3 56 65 Extra-pulmonary TB 
(miliary) 





26 44 Extra-pulmonary TB 
(abdominal) 





5 36 39 Extra-pulmonary TB 
(nodal and abdominal) 





pus collections 4 
6 39 80 Extra-pulmonary TB 
(nodal) 
Nodal 519 137 Lymph nodes 
and cold 
abscesses 
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Table 3: Factors associated with prolonged course of paradoxical TB-IRIS (defined as 
TB-IRIS symptoms lasting longer than 90 days) (n=181) 
 
 TB-IRIS symptoms 
> 90 days 
(n=73) (40.3%) 
TB-IRIS symptoms 












Age (years) 31 (26, 35) 31 (27, 37) 0.32 












CD4 count prior to ART 
(cells/μl) (n=170) 
57.5 (29, 91.2) 
 




CD4 count at TB-IRIS 
(cells/μl) (n=89) 
117 (71.7, 193.5) 116 (69, 262.5) 0.77 
Previous TB (n=180) 15 (20.6) 30 (28) 0.34 
Drug-resistant TB 
(n=181)1 
10 (13.7) 4 (3.7) 0.02 
Initial TB diagnosis 
with extra-pulmonary 
features (n=181) 
49 (67.1) 66 (61.1) 0.5 
Initial TB diagnosis 
with lymph node 
involvement (n=178) 
25 (34.2) 19 (18.1) 0.02 
Duration from TB 
treatment to ART 
(days)(n=181) 
58 (33, 84) 56 (31, 79.5) 0.8 
Duration from ART to 
IRIS onset (days) 
(n=181) 
13 (7, 23) 
 




Hospitalised at time of 
IRIS diagnosis (n=176) 
25 (34.2) 58 (56.3) 0.01 
IRIS lymph node 
involvement (n=181) 





49 (45.4) 0.07 
IRIS meningitis (n=181) 1 (1.4) 5 (4.7) 0.42 
IRIS abdominal 
involvement (n=181) 










Pulse rate at IRIS 
(n=120) 
121 (105, 133) 119 (108, 130) 0.96 
C-reactive protein 
(mg/l) (n=172) 
111 (74, 157.3) 95.5 (46.6, 165.7) 0.14 
Haemoglobin (g/dl) 
(n=113) 
9 (8, 10.1) 9.1 (8, 10.6) 0.62 
White cell count 5.9 (4.2, 7.2) 5.98 (4.38, 8.62) 0.33 
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(x 109/l) (n=109) 
ALT (IU/l) (n=157) 40 (25, 60) 34.5 (22, 47.7) 0.13 
Alkaline phosphatase 
(IU/l) (n=147) 
164 (113.5, 261.2) 164 (95, 278) 0.46 
Corticosteroid treatment 
for TB-IRIS 
48 (65.8%) 63 (58.3%) 0.35 
 
 
Footnote for Table 3: 
 
Medians (interquartile range) or number (%) are shown. Categorical variables were compared 
using Fisher’s exact test and continuous variables using Wilcoxon rank sum test. Pulse rate 
and laboratory values refer to the value obtained when the patient was first assessed with TB-
IRIS symptoms, unless otherwise stated. Numbers in brackets after the variable name refer to 
the number of patients for whom that variable was available. 
 
1 Among 14 patients with drug resistant TB 4 had rifampicin mono-resistance, 2 had isoniazid 
mono-resistance and 8 had resistance to rifampicin and isoniazid. The reference group is 
combined culture negative, culture not done and drug sensitive. 
 
Abbreviations: ALT = alanine transferase, ART = antiretroviral therapy, IRIS = immune 
reconstitution inflammatory syndrome, TB = tuberculosis, WHO = World Health 
Organisation. 
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Table 4: Odds ratios for univariate (unadjusted) and multivariate (adjusted) logistic 
regression models predicting the development of prolonged TB-IRIS 
 









(per 1 year increase) 0.97 (0.93-1.01) 0.16 0.98 (0.94-1.05) 0.48 
Male gender 0.72 (0.38-1.35) 0.31 0.80 (0.39-1.63) 0.54 
Initial TB diagnosis 
with lymph node 
involvement 2.36 (1.18-4.76) 0.02 1.79 (0.81-3.98) 0.15 
Drug-resistant TB 4.13 (1.32-15.56) 0.02 3.26 (0.97-12.99) 0.07 
Hospitalised at time 
of IRIS diagnosis 
 
0.40 (0.22-0.75) 0.004 0.5 (0.25-0.99) 0.05 
IRIS lymph node 
involvement 3.01 (1.63-5.65) 0.0005 2.27 (1.13-4.59) 0.02 
IRIS pulmonary 
involvement 0.54 (0.29-1.02) 0.06 0.65 (0.32-1.30) 0.23 
BCH cohort1 0.06 (0.01-0.18) < 0.0001 Not included  
Observational 




Footnote for Table 4: 
 
1 Reference cohort was randomized controlled trial 
 
Abbreviations: BCH=Brooklyn Chest Hospital, IRIS = immune reconstitution inflammatory 
syndrome, TB = tuberculosis 
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Table 5: Cox proportional hazards model predicting time to resolution of TB- IRIS 
symptoms 
 
 Adjusted HR (95% CI) p-value 
Age (per 1 year increase) 0.99 (0.97-1.01) 0.51 
Male gender 1.22 (0.86-1.74) 0.27 
Initial TB diagnosis with lymph 
node involvement 
0.75 (0.50-1.15) 0.19 
Drug-resistant TB 0.60 (0.34-1.08) 0.09 
Hospitalised at time of IRIS 
diagnosis 
1.28 (0.92-1.78) 0.14 
IRIS pulmonary involvement 1.29 (0.92-1.81) 0.14 
IRIS lymph node involvement 0.55 (0.38-0.78) 0.0009 
 
Footnote for Table 5:  
 
Abbreviations: IRIS = immune reconstitution inflammatory syndrome, TB = tuberculosis 
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Table 6: Factors associated with relapse of paradoxical TB-IRIS after discontinuing 28 
days of prednisone in the randomised controlled trial (n=43) 
Relapse  
(n=9)   (21%) 
No Relapse  
(n=34)   (79%) 
p-value for 
comparison 
Age (years) (n=43) 
Gender (n=43) 
  Female 
  Male 
34 (30, 37) 
8 (88.9%) 
1 (11.1%) 





WHO stage (n=43) 
  Stage 3 
  Stage 4 
CD4 pre ART (cells/ul) (n=43) 
CD4 at enrolment (cells/ul) (n=40) 
CD4 at week 4 (cells/ul) (n=36) 
Change in CD4 0-4 weeks (n=34) 
VL at enrolment (IU/ml) (n=33) 
VL at week 4 (IU/ml) (n=21) 
3 (33.3%) 
6 (66.7%) 
57 (39, 93) 
118 (93.5, 183) 
134 (85.5, 240) 
0 (-17.5, 91) 
470 (243, 790) 
339.5 (49, 872) 
19 (56%) 
15 (44%) 
55.5 (30, 107)  
141.5 (81.7, 242) 
170 (84, 246) 
17 (-19, 73.5) 
515 (145, 1325) 








Previous TB (n=43) 







Duration TB Rx to ART in days (n=43) 
Duration ART to IRIS in days (n=42) 
Duration IRIS to enrolment/steroids in 
days (n=42) 
60 (35, 77) 
12 (7, 28) 
18 (14, 29) 
65 (44, 85.5) 
14 (7, 21) 




TB IRIS manifestations (n=43) 
   New/recurrent lymphadenopathy  
   Or cold abscess  
   New/worsening pulmonary infiltrate  
   New/worsening serous effusion  
   Recurrent symptoms & consistent     
   radiography, but without baseline      
   radiography available for comparison 
   Abdominal  




















Karnofsky score at enrolment (n=42) 
Karnofsky score week 2 (n=39) 
Karnofsky score week 4 (n=39) 
Hospitalised at enrolment (n=43) 
50 (30, 72.5) 
85 (60, 90) 
90 (70, 95) 
2 (22.2%) 
70 (52.5, 80) 
90 (80, 90) 






Pulse rate at enrolment (n=43) 
Pulse rate week 2 (n=43) 
Pulse rate week 4 (n=43) 
121 (105, 132) 
114 (91, 120) 
116 (99, 118) 
116 (107, 130) 
104 (87.7, 119) 




CRP at enrolment (mg/l) (n=43) 
CRP week 2 (mg/l) (n=41) 
CRP week 4 (mg/l) (n=42) 
Change in CRP 0-4 wk (n=42) 
Haemoglobin at enrolment  (g/dl) (n=42) 
WCC at enrolment (x 109/l) (n=42) 
Neutrophils at enrolment (x 109/l) (n=40) 
Alk Phos at enrolment (IU/l) (n=43) 
Alk Phos at week 2 (IU/l) (n=31) 
118 (74, 128) 
37 (26, 47) 







93 (42.5, 152.5) 
29 (10.7, 48.7) 
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Alk Phos at week 4 (IU/l) (n=32) 
Change in Alk Phos 0-2 wk (n=31) 
Change in Alk Phos 0-4 wk (n=32) 
ALT at enrolment (IU/l) (n=43) 
ALT week 2 (IU/l) (n=27) 
ALT week 4 (IU/l) (n=21) 
Change in ALT 0-2 wk (n=27) 
Change in ALT 0-4 wk (n=21) 
247 (191, 316) 
+21.5 (-59, 94) 
+40 (-22, 86.5) 
40 (25, 58) 
51 (32, 79.5) 
36.5 (29, 69) 
28 (4.5, 31.5) 
+15 (3, 21) 
123 (77, 228) 
-53 (-115, -29.5) 
-42 (-101, -17) 
35.5 (19, 52) 
41 (25.5, 62) 
34 (30, 50.5) 
-0.5 (-13.5, 6.5) 









Clinical signs (n=43) 
   Fever 












Footnote for Table 6: 
 
Medians (interquartile range) or number (%) are shown. Categorical variables were compared 
using Fisher’s exact test and continuous variables using Wilcoxon rank sum test. Numbers in 
brackets after the variable refer to the number of patients for whom that variable was 
available. Demographic and clinical variables were available for all patients. Enrolment, week 
2 and week 4 in this table refer to those scheduled visits during the clinical trial. 
 
Abbreviations: Alk Phos = alkaline phosphatase, ALT = alanine transferase, ART = 
antiretroviral therapy, CRP = C-reactive protein, IRIS = immune reconstitution inflammatory 
syndrome, Rx=therapy, TB = tuberculosis, VL = HIV viral load, WCC = white cell count, 
WHO = World Health Organisation.  
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Legends for Figures: 
 
Figure 1: Inclusion and exclusion of patients in the prolonged TB-IRIS analyses 
The total study population included 216 TB-IRIS patients from 3 prior studies (1 randomised 
controlled trial and 2 prospective observational cohort studies). The analyses comparing those 
who experienced a prolonged course of TB IRIS symptoms (defined as lasting more than 90 
days) to those that did not experience a prolonged course of TB IRIS included 181 patients. 
Reasons for exclusion of 35 patients from these analyses are shown. 
 
Abbreviations: ART = antiretroviral therapy, BCH = Brooklyn Chest Hospital, IRIS = 
immune reconstitution inflammatory syndrome, RCT = randomised controlled trial, TB = 
tuberculosis. 
 
Figure 2: Inclusion of participants in the analysis of relapse after completing a 4-week 
course of prednisone 
This analysis included participants who were randomised to receive prednisone in the 
randomised controlled trial (RCT). Patients who relapsed with TB-IRIS symptoms after 
stopping 28 days of prednisone and were initiated on open label prednisone were compared to 
those who did not. Patients were excluded if they had an alternative reason for clinical 
deterioration or if they died before 4 weeks or switched to open label prednisone before 
completing 4 weeks of prednisone as study drug because of clinical deterioration during this 
time. Four patients were excluded from this analysis because they were found to have 













Total IRIS cohort 
n=216 
14 Died before 90 
days & IRIS 
resolution 
17 Lost to follow up 
before 90 days & IRIS  
resolution 
4 IRIS start date 
missing 
Number of individuals analysed 
n=181 
TB-IRIS symptoms 
lasted ≤ 90 days 
n=108 
 TB-IRIS symptoms 
lasted > 90 days 
n=73 




















































n = 110 
Placebo 
n = 55 
Prednisone 
n = 55 
5 Switched To open 
label steroids during 4 
weeks	  
Weeks	  
4 Rifampicin resistant1 
2 Died during 4 weeks 
1 Excluded due to 
incorrect information 
given at enrolment 
Relapsed requiring 
steroids 
n = 9 
No relapse 
n = 34	  
Number analysed 
n = 43 
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Legends for Supplementary Figures 
 
Supplementary Figure 1: Distribution of TB-IRIS duration 
This graph shows the number and proportion of patients who had a duration of TB-IRIS 
symptoms within each of the specified duration categories (in days) displayed on the x-axis. 
172 patients who had a known TB-IRIS start and end date were included. 
 
Supplementary Figure 2: Kaplan-Meier plot showing time to TB-IRIS resolution 
The graph shows the comparison between patients who had TB-IRIS lymph node 
involvement to those patients who did not in terms of time to TB-IRIS resolution. Resolution 
was more rapid in those without lymph node involvement (p<0.0001, log-rank test). 
 
Supplementary Figure 3: Alkaline phosphatase and alanine transferase concentrations 
during the 4-week course of prednisone on the RCT, comparing those who relapsed with 
TB-IRIS symptoms after stopping prednisone to those who did not 
In univariate analysis, lower reduction in alkaline phosphatase from 0 to 4 weeks (p=0.03) 
and lower reduction in ALT from 0 to 4 weeks (p=0.04) were significantly associated with 
subsequent relapse (see Table 5).  
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Supplementary Figure 1 
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Assistance with the process of manuscript preparation and submission is available 
from BioMed Central customer support team. See 'About this journal' for information about 
policies and the refereeing process. We also provide a collection of links to useful tools and 
resources for scientific authors on our page. 
 
Criteria 
Research articles should report on original primary research, but may report on systematic 
reviews of published research provided they adhere to the appropriate reporting guidelines 
which are detailed in our Editorial Policies. Please note that non-commissioned pooled 
analyses of selected published research will not be considered. 
 
Submission process 
Manuscripts must be submitted by one of the authors of the manuscript, and should not be 
submitted by anyone on their behalf. The submitting author takes responsibility for the article 
during submission and peer review. 
Please note that BMC Infectious Diseases levies an article-processing charge on all accepted 
Research articles; if the submitting author's institution is a BioMed Central member the cost 
of the article-processing charge may be covered by the membership (see About page for 
detail). Please note that the membership is only automatically recognised on submission if the 
submitting author is based at the member institution. 
To facilitate rapid publication and to minimize administrative costs, BMC Infectious 
Diseases prefers online submission. 
Files can be submitted as a batch, or one by one. The submission process can be interrupted at 
any time; when users return to the site, they can carry on where they left off. 
See below for examples of word processor and graphics file formats that can be accepted for 
the main manuscript document by the online submission system. Additional files of any type, 
such as movies, animations, or original data files, can also be submitted as part of the 
manuscript. 
During submission you will be asked to provide a cover letter. Use this to explain why your 
manuscript should be published in the journal, to elaborate on any issues relating to our 
editorial policies in the'About BMC Infectious Diseases' page, and to declare any potential 
competing interests. You will be also asked to provide the contact details (including email 
addresses) of potential peer reviewers for your manuscript. These should be experts in their 
field, who will be able to provide an objective assessment of the manuscript. Any suggested 
peer reviewers should not have published with any of the authors of the manuscript within the 
past five years, should not be current collaborators, and should not be members of the same 
research institution. Suggested reviewers will be considered alongside potential reviewers 
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recommended by the Editorial team, Editorial Advisors, Section Editors and Associate 
Editors. 
Assistance with the process of manuscript preparation and submission is available 
from BioMed Central customer support team. 
We also provide a collection of links to useful tools and resources for scientific authors on 
our Useful Tools page. 
File formats 
The following word processor file formats are acceptable for the main manuscript document: 
• Microsoft word (DOC, DOCX)
• Rich text format (RTF)
• Portable document format (PDF)
• TeX/LaTeX (use BioMed Central's TeX template)
• DeVice Independent format (DVI)
TeX/LaTeX users: Please use BioMed Central's TeX template and BibTeX stylefile if you use 
TeX format. During the TeX submission process, please submit your TeX file as the main 
manuscript file and your bib/bbl file as a dependent file. Please also convert your TeX file 
into a PDF and submit this PDF as an additional file with the name 'Reference PDF'. This 
PDF will be used by internal staff as a reference point to check the layout of the article as the 
author intended. Please also note that all figures must be coded at the end of the TeX file and 
not inline. 
If you have used another template for your manuscript, or if you do not wish to use BibTeX, 
then please submit your manuscript as a DVI file. We do not recommend converting to RTF. 
For all TeX submissions, all relevant editable source must be submitted during the submission 
process. Failing to submit these source files will cause unnecessary delays in the publication 
procedures. 
Publishing Datasets 
Through a special arrangement with LabArchives, LLC, authors submitting manuscripts to 
BMC Infectious Diseases can obtain a complimentary subscription to LabArchives with an 
allotment of 100MB of storage. LabArchives is an Electronic Laboratory Notebook which 
will enable scientists to share and publish data files in situ; you can then link your paper to 
these data. Data files linked to published articles are assigned digital object identifiers (DOIs) 
and will remain available in perpetuity. Use of LabArchives or similar data publishing 
services does not replace preexisting data deposition requirements, such as for nucleic acid 
sequences, protein sequences and atomic coordinates. 
Instructions on assigning DOIs to datasets, so they can be permanently linked to publications, 
can be found on the LabArchives website. Use of LabArchives’ software has no influence on 
the editorial decision to accept or reject a manuscript. 
Authors linking datasets to their publications should include an Availability of supporting 
data section in their manuscript and cite the dataset in their reference list. 
Preparing main manuscript text 
General guidelines of the journal's style and language are given below. 
Overview of manuscript sections for Research articles 
Manuscripts for Research articles submitted to BMC Infectious Diseases should be divided 







• Results and discussion
• Conclusions







• Illustrations and figures (if any)
• Tables and captions
• Preparing additional files
The Accession Numbers of any nucleic acid sequences, protein sequences or atomic 
coordinates cited in the manuscript should be provided, in square brackets and include the 
corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, 
DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116]. 
The databases for which we can provide direct links are: EMBL Nucleotide Sequence 
Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), 
Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein 
Database (Swiss-Prot). 
For reporting standards please see the information in the About section. 
Title page 
The title page should: 
• provide the title of the article
• list the full names, institutional addresses and email addresses for all authors
• indicate the corresponding author
Please note: 
• the title should include the study design, for example "A versus B in the treatment of
C: a randomized controlled trial X is a risk factor for Y: a case control study"
• abbreviations within the title should be avoided
Abstract 
The Abstract of the manuscript should not exceed 350 words and must be structured into 
separate sections: Background, the context and purpose of the study; Methods, how the 
study was performed and statistical tests used; Results, the main findings; Conclusions, brief 
summary and potential implications. Please minimize the use of abbreviations and do not cite 
references in the abstract. Trial registration, if your research article reports the results of a 
controlled health care intervention, please list your trial registry, along with the unique 
identifying number (e.g. Trial registration: Current Controlled Trials ISRCTN73824458). 
Please note that there should be no space between the letters and numbers of your trial 
registration number. We recommend manuscripts that report randomized controlled trials 
follow the CONSORT extension for abstracts. 
Keywords 
Three to ten keywords representing the main content of the article. 
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Background 
The Background section should be written in a way that is accessible to researchers without 
specialist knowledge in that area and must clearly state - and, if helpful, illustrate - the 
background to the research and its aims. Reports of clinical research should, where 
appropriate, include a summary of a search of the literature to indicate why this study was 
necessary and what it aimed to contribute to the field. The section should end with a brief 
statement of what is being reported in the article. 
Methods 
The methods section should include the design of the study, the setting, the type of 
participants or materials involved, a clear description of all interventions and comparisons, 
and the type of analysis used, including a power calculation if appropriate. Generic drug 
names should generally be used. When proprietary brands are used in research, include the 
brand names in parentheses in the Methods section. 
For studies involving human participants a statement detailing ethical approval and consent 
should be included in the methods section. For further details of the journal's editorial policies 
and ethical guidelines see 'About this journal'. 
For further details of the journal's data-release policy, see the policy section in 'About this 
journal'. 
Results and discussion 
The Results and discussion may be combined into a single section or presented separately. 
Results of statistical analysis should include, where appropriate, relative and absolute risks or 
risk reductions, and confidence intervals. The Results and discussion sections may also be 
broken into subsections with short, informative headings. 
Conclusions 
This should state clearly the main conclusions of the research and give a clear explanation of 
their importance and relevance. Summary illustrations may be included. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at first use, and a list of 
abbreviations can be provided, which should precede the competing interests and authors' 
contributions. 
Competing interests 
A competing interest exists when your interpretation of data or presentation of information 
may be influenced by your personal or financial relationship with other people or 
organizations. Authors must disclose any financial competing interests; they should also 
reveal any non-financial competing interests that may cause them embarrassment were they to 
become public after the publication of the manuscript. 
Authors are required to complete a declaration of competing interests. All competing interests 
that are declared will be listed at the end of published articles. Where an author gives no 
competing interests, the listing will read 'The author(s) declare that they have no competing 
interests'. 
When completing your declaration, please consider the following questions: 
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Financial competing interests 
• In the past three years have you received reimbursements, fees, funding, or salary 
from an organization that may in any way gain or lose financially from the publication 
of this manuscript, either now or in the future? Is such an organization financing this 
manuscript (including the article-processing charge)? If so, please specify. 
• Do you hold any stocks or shares in an organization that may in any way gain or lose 
financially from the publication of this manuscript, either now or in the future? If so, 
please specify. 
• Do you hold or are you currently applying for any patents relating to the content of the 
manuscript? Have you received reimbursements, fees, funding, or salary from an 
organization that holds or has applied for patents relating to the content of the 
manuscript? If so, please specify. 
• Do you have any other financial competing interests? If so, please specify. 
 
Non-financial competing interests 
Are there any non-financial competing interests (political, personal, religious, ideological, 
academic, intellectual, commercial or any other) to declare in relation to this manuscript? If 
so, please specify. 
If you are unsure as to whether you, or one your co-authors, has a competing interest please 
discuss it with the editorial office. 
 
Authors' contributions 
In order to give appropriate credit to each author of a paper, the individual contributions of 
authors to the manuscript should be specified in this section. 
According to ICMJE guidelines, An 'author' is generally considered to be someone who has 
made substantive intellectual contributions to a published study. To qualify as an author one 
should 1) have made substantial contributions to conception and design, or acquisition of 
data, or analysis and interpretation of data; 2) have been involved in drafting the manuscript 
or revising it critically for important intellectual content; 3) have given final approval of the 
version to be published; and 4) agree to be accountable for all aspects of the work in ensuring 
that questions related to the accuracy or integrity of any part of the work are appropriately 
investigated and resolved. Each author should have participated sufficiently in the work to 
take public responsibility for appropriate portions of the content. Acquisition of funding, 
collection of data, or general supervision of the research group, alone, does not justify 
authorship. 
We suggest the following kind of format (please use initials to refer to each author's 
contribution): AB carried out the molecular genetic studies, participated in the sequence 
alignment and drafted the manuscript. JY carried out the immunoassays. MT participated in 
the sequence alignment. ES participated in the design of the study and performed the 
statistical analysis. FG conceived of the study, and participated in its design and coordination 
and helped to draft the manuscript. All authors read and approved the final manuscript. 
All contributors who do not meet the criteria for authorship should be listed in an 
acknowledgements section. Examples of those who might be acknowledged include a person 
who provided purely technical help, writing assistance, or a department chair who provided 




You may choose to use this section to include any relevant information about the author(s) 
that may aid the reader's interpretation of the article, and understand the standpoint of the 
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author(s). This may include details about the authors' qualifications, current positions they 
hold at institutions or societies, or any other relevant background information. Please refer to 
authors using their initials. Note this section should not be used to describe any competing 
interests. 
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intellectual content, but who does not meet the criteria for authorship. Please also include the 
source(s) of funding for each author, and for the manuscript preparation. Authors must 
describe the role of the funding body, if any, in design, in the collection, analysis, and 
interpretation of data; in the writing of the manuscript; and in the decision to submit the 
manuscript for publication. Please also acknowledge anyone who contributed materials 
essential for the study. If a language editor has made significant revision of the manuscript, 
we recommend that you acknowledge the editor by name, where possible. 
The role of a scientific (medical) writer must be included in the acknowledgements section, 
including their source(s) of funding. We suggest wording such as 'We thank Jane Doe who 
provided medical writing services on behalf of XYZ Pharmaceuticals Ltd.' 
Authors should obtain permission to acknowledge from all those mentioned in the 
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Endnotes 
Endnotes should be designated within the text using a superscript lowercase letter and all 
notes (along with their corresponding letter) should be included in the Endnotes section. 
Please format this section in a paragraph rather than a list. 
References 
All references, including URLs, must be numbered consecutively, in square brackets, in the 
order in which they are cited in the text, followed by any in tables or legends. Each reference 
must have an individual reference number. Please avoid excessive referencing. If automatic 
numbering systems are used, the reference numbers must be finalized and the bibliography 
must be fully formatted before submission. 
Only articles, clinical trial registration records and abstracts that have been published or are in 
press, or are available through public e-print/preprint servers, may be cited; unpublished 
abstracts, unpublished data and personal communications should not be included in the 
reference list, but may be included in the text and referred to as "unpublished observations" or 
"personal communications" giving the names of the involved researchers. Obtaining 
permission to quote personal communications and unpublished data from the cited colleagues 
is the responsibility of the author. Footnotes are not allowed, but endnotes are permitted. 
Journal abbreviations follow Index Medicus/MEDLINE. Citations in the reference list should 
include all named authors, up to the first six before adding 'et al.'.. 
Any in press articles cited within the references and necessary for the reviewers' assessment 
of the manuscript should be made available if requested by the editorial office. 
An Endnote style file is available. 
Examples of the BMC Infectious Diseases reference style are shown below. Please ensure that 
the reference style is followed precisely; if the references are not in the correct style they may 
have to be retyped and carefully proofread. 
All web links and URLs, including links to the authors' own websites, should be given a 
reference number and included in the reference list rather than within the text of the 
75	  
manuscript. They should be provided in full, including both the title of the site and the URL, 
as well as the date the site was accessed, in the following format: The Mouse Tumor Biology 
Database. http://tumor.informatics.jax.org/mtbwi/index.do. Accessed 20 May 2013. If an 
author or group of authors can clearly be associated with a web link, such as for weblogs, then 
they should be included in the reference. 
Examples of the BMC Infectious Diseases reference style 
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Feb 2000.
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Preparing illustrations and figures 
Illustrations should be provided as separate files, not embedded in the text file. Each figure 
should include a single illustration and should fit on a single page in portrait format. If a 
figure consists of separate parts, it is important that a single composite illustration file be 
submitted which contains all parts of the figure. There is no charge for the use of color 
figures. 
Please read our figure preparation guidelines for detailed instructions on maximising the 
quality of your figures. 
 
Formats 
The following file formats can be accepted: 
• PDF (preferred format for diagrams) 
• DOCX/DOC (single page only) 
• PPTX/PPT (single slide only) 
• EPS 






The legends should be included in the main manuscript text file at the end of the document, 
rather than being a part of the figure file. For each figure, the following information should be 
provided: Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short 
title of figure (maximum 15 words); detailed legend, up to 300 words. 
Please note that it is the responsibility of the author(s) to obtain permission from the 




Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 3 
etc.). Tables should also have a title (above the table) that summarizes the whole table; it 
should be no longer than 15 words. Detailed legends may then follow, but they should be 
concise. Tables should always be cited in text in consecutive numerical order. 
Smaller tables considered to be integral to the manuscript can be pasted into the end of the 
document text file, in A4 portrait or landscape format. These will be typeset and displayed in 
the final published form of the article. Such tables should be formatted using the 'Table object' 
in a word processing program to ensure that columns of data are kept aligned when the file is 
sent electronically for review; this will not always be the case if columns are generated by 
simply using tabs to separate text. Columns and rows of data should be made visibly distinct 
by ensuring that the borders of each cell display as black lines. Commas should not be used to 
indicate numerical values. Color and shading may not be used; parts of the table can be 
highlighted using symbols or bold text, the meaning of which should be explained in a table 
legend. Tables should not be embedded as figures or spreadsheet files. 
Larger datasets or tables too wide for a portrait page can be uploaded separately as additional 
files. Additional files will not be displayed in the final, laid-out PDF of the article, but a link 
will be provided to the files as supplied by the author. 
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls ) or 
comma separated values (.csv). As with all files, please use the standard file extensions. 
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Preparing additional files 
Although BMC Infectious Diseases does not restrict the length and quantity of data included 
in an article, we encourage authors to provide datasets, tables, movies, or other information as 
additional files. 
Please note: All Additional files will be published along with the article. Do not include files 
such as patient consent forms, certificates of language editing, or revised versions of the main 
manuscript document with tracked changes. Such files should be sent by email 
to editorial@biomedcentral.com, quoting the Manuscript ID number. 
Results that would otherwise be indicated as "data not shown" can and should be included as 
additional files. Since many web links and URLs rapidly become broken, BMC Infectious 
Diseases requires that supporting data are included as additional files, or deposited in a 
recognized repository. Please do not link to data on a personal/departmental website. The 
maximum file size for additional files is 20 MB each, and files will be virus-scanned on 
submission. 
Additional files can be in any format, and will be downloadable from the final published 
article as supplied by the author. We recommend CSV rather than PDF for tabular data. 
Certain supported files formats are recognized and can be displayed to the user in the browser. 
These include most movie formats (for users with the Quicktime plugin), mini-websites 
prepared according to our guidelines, chemical structure files (MOL, PDB), geographic data 
files (KML). 
If additional material is provided, please list the following information in a separate section of 
the manuscript text: 
• File name (e.g. Additional file 1)
• File format including the correct file extension for example .pdf, .xls, .txt, .pptx
(including name and a URL of an appropriate viewer if format is unusual)
• Title of data
• Description of data
Additional files should be named "Additional file 1" and so on and should be referenced 
explicitly by file name within the body of the article, e.g. 'An additional movie file shows this 
in more detail [see Additional file 1]'. 
Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and should be 
viewable using free or widely available tools. The following are examples of suitable formats. 
• Additional documentation
o PDF (Adode Acrobat)
• Animations
o SWF (Shockwave Flash)
• Movies
o MP4 (MPEG 4)
o MOV (Quicktime)
• Tabular data
o XLS, XLSX (Excel Spreadsheet)
o CSV (Comma separated values)
As with figure files, files should be given the standard file extensions. 
Mini-websites 
Small self-contained websites can be submitted as additional files, in such a way that they 
will be browsable from within the full text HTML version of the article. In order to do this, 
please follow these instructions: 
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1. Create a folder containing a starting file called index.html (or index.htm) in the root.
2. Put all files necessary for viewing the mini-website within the folder, or sub-folders.
3. Ensure that all links are relative (ie "images/picture.jpg" rather than
"/images/picture.jpg" or "http://yourdomain.net/images/picture.jpg" or "C:\Documents
and Settings\username\My Documents\mini-website\images\picture.jpg") and no link
is longer than 255 characters.
4. Access the index.html file and browse around the mini-website, to ensure that the
most commonly used browsers (Internet Explorer and Firefox) are able to view all
parts of the mini-website without problems, it is ideal to check this on a different
machine.
5. Compress the folder into a ZIP, check the file size is under 20 MB, ensure that
index.html is in the root of the ZIP, and that the file has .zip extension, then submit as
an additional file with your article.
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Appendix 3: Additional analyses not included in manuscript 
Supplementary Table 1: Odds ratios for univariate (unadjusted) and multivariate 
(adjusted) logistic regression models predicting the development of prolonged TB-IRIS 










(per 1 year increase) 0.98	  (0.93,	  1.03) 0.36 0.99	  (0.94,	  1.05) 0.723
Male gender 0.70	  (0.34,	  1.40) 0.31 0.63	  (0.28,	  1.41) 0.264
Initial TB diagnosis 
with lymph node 
involvement 2.36	  (1.08,	  5.39) 0.03 1.79	  (0.75,	  4.46) 0.20
Drug-resistant TB 2.79	  (0.88,	  10.60) 0.10 2.31	  (0.69,	  9.11) 0.19
Hospitalised at time 
of IRIS diagnosis 0.98	  (0.48,	  2.03) 0.96 1.16	  (0.53,	  2.57) 0.71
IRIS lymph node 
involvement 2.33	  (1.19,	  4.64) 0.01 1.90	  (0.89,	  4.09) 0.10
IRIS pulmonary 
involvement 0.59	  (0.29,	  1.17) 0.13 0.61	  (0.28,	  1.32) 0.21
Due to the potential bias around the BCH cohort and hospitalization a sensitivity analysis was 
performed excluding all individuals in the BCH cohort. Both univariate and multivariate 
regression models were assessed as shown in the table above and although, as expected, the 
number of variables with statistically significant associations decreased, the direction	  and size 
of the effects remained largely the same. However, hospitalization was no longer associated 
with prolonged TB-IRIS (aOR 1.16, 95%CI=0.53-2.57, p=0.71).
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Supplementary Table 2: Cox proportional hazards model predicting time to resolution 
of TB- IRIS symptoms excluding BCH cohort 
Adjusted HR (95% CI) p-value 
Age (per 1 year increase) 0.99 (0.96-1.01) 0.36 
Male gender 1.42 (0.92-2.18) 0.11 
Initial TB diagnosis with lymph 
node involvement 
0.72 (0.44-1.17) 0.18 
Drug-resistant TB 0.65 (0.36-1.20) 0.17 
Hospitalised at time of IRIS 
diagnosis 
0.93 (0.62-1.40) 0.73 
IRIS pulmonary involvement 1.23 (0.82-1.83) 0.32 
IRIS lymph node involvement 0.60 (0.40-0.89) 0.01 
In the Cox proportional hazards model, even when the BCH cohort was excluded (results in 
above table), IRIS lymph node involvement remained statistically significantly associated 
with a lower likelihood of IRIS resolution (HR 0.60, 95%CI=0.40-0.89; p = 0.01). 
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Supplementary Table 3: Competing risks model of time to TB-IRIS resolution  (with 
competing risk of death) 
 
 Mortality  TB-IRIS resolution 
Characteristic Adjusted HR 
(95% CI) 





0.81 (0.29-2.32) 0.70 1.29 (0.92-1.81) 0.13 
IRIS lymph node 
involvement 
0.37 (0.11-1.18 0.09 0.55 (0.38-0.78) 0.0009 
Initial TB diagnosis with 
lymph node involvement 
2.13 (0.72-6.26) 0.17 0.75 (0.49-1.15) 0.19 
Hospitalised at time of 
IRIS diagnosis 
9.51 (2.05-44.04) 0.004 1.28 (0.92-1.78) 0.14 
Age (per 1 year increase) 1.04 (0.99-1.10) 0.14 0.99 (0.97-1.01) 0.51 
Male gender 0.32 (0.09-1.14) 0.08 1.22 (0.86-1.74) 0.27 
Drug-resistant TB 1.96 (0.42-9.22) 0.39 0.60 (0.34-1.08) 0.09 
 
Competing risks models were analysed to account for the competing risk of death and IRIS 
resolution. The model demonstrated similar findings to the Cox proportional hazards model as 































Appendix 4: Data capture sheet 
IRIS_No	   RCT_No	   Rel_req_ster	   Age	   Gender	   WHO_Stage	   CD4_preART	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ster_dose2	   hosp.iris_	   Kscore_wk0	   Kscore_wk2	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   iris_symp	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lymph.nodes	   iris_LN0baseline_site	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   iris_nodalVSnon_nodal	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   stop_steroid	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   CD4_wk4_old	   VL_wk0_old	   VL_wk4_old	   alp_0_2	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diff_tbRx_art	   diff_art_iris	   diff_iris_ster	   diff_ster	   diff_iris	   diff_cd4_art_iris	   aa	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ltf.outcome	   steroids	   dur_iris	   censor.yn	   prolong.iris	   DR.tb	   cd4_0_4	   alt_0_4	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crp_0_4	   dead	   ongoing	   yr.long	   cohort	  
